Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 17Active not recruiting 8Not yet recruiting 6Completed 5Unknown 3Terminated 3Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Lymphoma, B-Cell 1

Interventions

Rituximab 21Cyclophosphamide 15Etoposide 11Vincristine 9Prednisone 9Doxorubicin 8Cytarabine 8Filgrastim 7Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Melphalan 5Dexamethasone 4Carmustine 4Bendamustine Hydrochloride 4loncastuximab tesirine 3ibrutinib 3Tacrolimus 3Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Gemcitabine 3Calcium Dobesilate 3CT-P10 3Busulfan 3venetoclax 2sargramostim 2polatuzumab vedotin 2pembrolizumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Large B-Cell, Diffuse × polatuzumab vedotin × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04535102 2022-05-09

POLA+BR for Relapsed or Refractory DLBCL

University of Colorado, Denver

Phase 2 Withdrawn
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡